Target intelligence / Profile preview

Off-target mRNAs with partial complementarity to APPL2 siRNA guide strand

Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Off-target mRNAs with partial complementarity to the APPL2 siRNA guide strand refer to a collection of unintended transcripts that are silenced during RNA interference (RNAi) experiments or therapies targeting the APPL2 gene (Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2). This phenomenon occurs when the 'seed region' of the siRNA—typically nucleotides 2 through 8—binds to the 3' untranslated regions (UTRs) of non-target mRNAs, triggering their degradation or inhibiting their translation in a manner similar to endogenous microRNAs (Jackson et al., 2003, Nature Biotechnology). APPL2 itself is an important adaptor protein involved in endosomal signaling, insulin sensitivity, and chromatin remodeling (UniProt, Q8NEU8). Because APPL2 is a potential therapeutic target in metabolic and inflammatory diseases, the specificity of its knockdown is critical. Unintended silencing of off-target mRNAs can lead to significant cellular toxicity and misleading phenotypic data, which are major hurdles in the development of siRNA-based therapeutics (Birmingham et al., 2006, Nature Methods). Mitigation strategies include the use of chemical modifications to the siRNA backbone and advanced bioinformatic algorithms to select sequences with minimal transcriptome-wide seed complementarity.

Other names
siRNA off-target transcriptsSeed-mediated off-target effectsmiRNA-like off-target silencingNon-specific APPL2 siRNA effects
02

Mechanism of action

Seed-sequence mediated binding of the siRNA guide strand to the 3' untranslated region (UTR) of non-target mRNAs, leading to RISC-mediated degradation or translational repression.

03

Biological functions

RNA interferencePost-transcriptional gene regulationGene silencing
04

Disease associations

Drug-induced toxicityOff-target phenotypic artifacts
05

Safety considerations

Unintended silencing of essential genesCellular toxicityConfounding experimental resultsPotential for adverse clinical side effects
06

Interacting drugs

APPL2 siRNA
07

Biomarkers

Transcriptome-wide expression profilingRNA-seq signaturesReporter gene assays for seed-match toxicity

Beyond the preview

Go deeper on Off-target mRNAs with partial complementarity to APPL2 siRNA guide strand.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target mRNAs with partial complementarity to APPL2 siRNA guide strand.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call